ArticleJournal of enzyme inhibition and medicinal chemistry2019
Inhibition of acetylcholinesterase and butyrylcholinesterase with uracil derivatives: kinetic and computational studies.
Article in Journal of enzyme inhibition and medicinal chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 110 citations in OpenAlex.
- Effects of Chlorine and Methyl Substitution on Structure, IR, and Raman Spectra of the Biomolecule 6-Chloro-3-methyluracil in Isolated and Solid States and in Base-Pair Formation.Molecules (Basel, Switzerland) · 2026Article
- Design, Synthesis, and Evaluation of Halogenated Indoles Amines as Acetylcholinesterase Inhibitors: Integrated In-Vitro and In-Silico Approaches.Chemistry & biodiversity · 2026Article
- Natural Chiral Scaffolds in Alzheimer's Disease: Therapeutic Potential, Mechanism, and Clinical Aspects.BioMed research international · 2026Review
- Investigation of the multifunctional profile of dihydroquinazoline derivatives as potential therapeutics for Alzheimer's disease.RSC medicinal chemistry · 2025Article
- Innovative approaches in acetylcholinesterase inhibition: a pathway to effective Alzheimer's disease treatment.Molecular diversity · 2025Review
- Silodosin as a Novel Inhibitor of Acetylcholinesterase, Butyrylcholinesterase, and BETA-Secretase 1: In Vitro and In Silico Studies.ACS omega · 2025Article
- Investigation of Biopesticides for the Pest Control Through Inhibition of the Acetylcholinesterase Purified from Loxostege sticticalis (L.) (Lepidoptera: Crambidae).Applied biochemistry and biotechnology · 2025Article
- Piperonal-derived Schiff base molecules as potential multi-target therapeutic agents against Alzheimer's and diabetes.Future medicinal chemistry · 2025Article
- Exploration of natural products for the development of promising cholinesterase inhibitors in Alzheimer's disease treatment.Heliyon · 2025Article
- Ternary Solid Dispersions as an Alternative Approach to Enhance Pharmacological Activity.Drug design, development and therapy · 2025Review
- The Role of Uridine in Health and Disease.Journal of inflammation research · 2025Review
- Phenylstyrylpyrimidine derivatives as potential multipotent therapeutics for Alzheimer's disease.RSC medicinal chemistry · 2024Article
- Development of Delivery Systems with Prebiotic and Neuroprotective Potential of Industrial-GradeMolecules (Basel, Switzerland) · 2024Article
- Synthesis of Novel Hydrazide-Hydrazone Compounds andACS omega · 2024Article
- Article
- Identification of coumarin derivatives targeting acetylcholinesterase for Alzheimer's disease by field-based 3D-QSAR, pharmacophore model-based virtual screening, molecular docking, MM/GBSA, ADME and MD Simulation study.Current research in structural biology · 2024Article
- Araucaria heterophylla oleogum resin essential oil is a novel aldose reductase and butyryl choline esterase enzymes inhibitor: in vitro and in silico evidence.Scientific reports · 2023Article
- In silico and in vitro studies confirm Ondansetron as a novel acetylcholinesterase and butyrylcholinesterase inhibitor.Scientific reports · 2023Article
- Characterization of Orange Peel Extract and Its Potential Protective Effect against Aluminum Chloride-Induced Alzheimer's Disease.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Cyclodextrin Derivatives as Promising Solubilizers to Enhance the Biological Activity of Rosmarinic Acid.Pharmaceutics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acetylcholinesterase (AChE) and Butyrylcholinesterase (BuChE) inhibitors are interesting compounds for different therapeutic applications, among which Alzheimer's disease. Here, we investigated the inhibition of these cholinesterases with uracil derivatives. The mechanism of inhibition of these enzymes was observed to be due to obstruction of the active site entrance by the inhibitors scaffold. Molecular docking and molecular dynamics (MD) simulations demonstrated the possible key interactions between the studied ligands and amino acid residues at different regions of the active sites of AChE and BuChE. Being diverse of the classical AChE and BuChE inhibitors, the investigated uracil derivatives may be used as lead molecules for designing new therapeutically effective enzyme inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.